Skip to content
Review

Angiotensin system modulation in focal segmental glomerulosclerosis: pharmacological basis and clinical implications

Jul 2026 · Expert Opinion on Pharmacotherapy · Vol 27, pp. 1293 - 1308 · 0 citations · 84 references
Medicine

TL;DR

New therapies, including dual AT1/endothelin-A antagonism and podocyte-targeted approaches (apecotrep), show promising proteinuria reductions but have not yet demonstrated clear benefits on hard renal outcomes, while biomarker-driven strategies may enable more tailored treatment, although their clinical impact remains to be established.

Abstract

ABSTRACT Introduction FSGS is a histological convergence point for biologically distinct conditions: primary immune-mediated, genetic, and secondary adaptive forms, each with its own pharmacological logic. ACE inhibitors and angiotensin receptor blockers have anchored its management for three decades on evidence drawn predominantly from non-FSGS populations. Areas covered Experimental and clinical literature from PubMed/MEDLINE, Embase, and Web of Science through 30 January 2026, covering angiotensin II–mediated podocyte injury, RAAS pharmacology across FSGS subtypes, and emerging strategies that extend or layer upon the RAAS backbone, including dual AT1/endothelin-A blockade, SGLT2 inhibition, and mineralocorticoid receptor antagonism, with additional podocyte-targeted and genotype-guided approaches. Expert opinion The clinical benefit of RAAS blockade appears to vary across FSGS subtypes. It likely targets a key pathogenic mechanism in secondary adaptive forms, while serving mainly as supportive antiproteinuric therapy in immune-mediated and genetic disease. Nonetheless, it remains a cornerstone of care. Emerging therapies, including dual AT1/endothelin-A antagonism (sparsentan) and podocyte-targeted approaches (apecotrep), show promising proteinuria reductions but have not yet demonstrated clear benefits on hard renal outcomes. Biomarker-driven strategies (e.g. anti-nephrin antibodies, APOL1 genotyping) may enable more tailored treatment, although their clinical impact remains to be established.

View source

Similar papers

Review Aug 2026

Evaluating sparsentan for the treatment of focal segmental glomerulosclerosis

ABSTRACT Introduction Focal segmental glomerulosclerosis (FSGS) represents a histopathologic pattern of glomerular injury rather than a single disease entity. In FSGS, prognosis varies substantially according to the degree of proteinuria. Despite optimized supportive therapy and, in presumed primary FSGS, immunosuppres...

Cristián Juanet, María José Soler, L. Zand et al. · 0 citations
Review Open access Aug 2026

Targeting Inflammation in Chronic Kidney Disease: Pathophysiological Insights and Emerging Therapeutic Strategies

Renin–angiotensin system inhibitors, sodium–glucose cotransporter-2 inhibitors, finerenone, and glucagon-like peptide-1 receptor agonists improve cardiorenal outcomes and have plausible anti-inflammatory actions, although inflammatory mediation remains unproven.

Aris Tsalouchos, P. Dattolo · 0 citations
Review Open access Sep 2026

A review of advances in research on mechanisms inhibiting kidney stone formation from a network pharmacology perspective

Nephrolithiasis is a prevalent, highly recurrent urological disorder affecting 1%–15% of the global population, with 5-year recurrence rates reaching up to 50%. While surgical interventions achieve acute stone clearance, they do not resolve underlying metabolic derangements, crystal-induced tubular injury, or chronic i...

Xu-Ming Zhang, Chao-Yue Ji, Wei-Guo Hu · 0 citations
Case report Open access Oct 2026

Mapping the preclinical therapeutic landscape of cirrhotic portal hypertension: a systematic evidence map.

INTRODUCTION AND OBJECTIVES Portal hypertension has a limited pharmacological armamentarium despite decades of preclinical therapeutic research. We mapped the experimental architecture of this literature, independently of reported treatment efficacy. MATERIALS AND METHODS PubMed/MEDLINE was searched from inception to...

Sergi Guixé-Muntet, Anabel Fernández-Iglesias, Verónica Arreaza-Gil et al. · 0 citations
Review Open access Oct 2026

Cardiorenal Syndrome: From Hemodynamic and Humoral Pathophysiology to New Frontiers in Modulation and Enabling Therapy—Part 2

The therapeutic landscape of cardiorenal syndrome (CRS) has evolved significantly, transitioning from historical cornerstones like angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) to modern neurohormonal modulation with angiotensin receptor–neprilysin inhibitors (ARNIs). This seco...

A. Mauriello, V. Cetoretta, Carmen Del Giudice et al. · 0 citations
Review Aug 2026

Emerging therapies for diabetic kidney disease: beyond SGLT2 inhibitors

This review summarizes contemporary guideline-directed therapy for DKD and examines emerging therapeutic strategies targeting complementary pathways implicated in kidney disease progression, which include novel incretin-based therapies, aldosterone synthase inhibitors, endothelin receptor antagonists, soluble guanylate...

Hua-Jing Ni, Simon Piggott, M. Festa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.